Journey Medical Corp 2024年度报告

FORM10-K or Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for thepast 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport. Yes☐No☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by anyof the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act). Yes☐No☒ The aggregate market value of voting stock held by non-affiliates of the registrant on June 30, 2024, the last business day of the registrant’s most recentlycompleted second quarter, was $50,127,341based on the last reported sale price of the registrant’s Common Stock on the Nasdaq Capital Market on that date of$5.50. Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. Portions of the registrant’s Proxy Statement for its 2025 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference in Part III of thisAnnual Report on Form 10-K. JOURNEY MEDICAL CORPORATIONANNUAL REPORT ON FORM 10-KTABLE OF CONTENTS PagePART I6Item 1.Business6Item 1A.Risk Factors24Item 1B.Unresolved Staff Comments58Item 1C.Cybersecurity59Item 2.Properties60Item 3.Legal Proceedings60Item 4.Mine Safety Disclosures60PART II61Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchasesof Equity Securities61Item 6.Reserved61Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations62Item 7A.Quantitative and Qualitative Disclosures About Market Risk69Item 8.Financial Statements and Supplementary Data69Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure69Item 9A.Controls and Procedures69Item 9B.Other Information70Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.70PART III71Item 10.Directors, Executive Officers and Corporate Governance71Item 11.Executive Compensation71Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters71Item 13.Certain Relationships and Related Transactions, and Director Independence71Item 14.Principal Accountant Fees and Services71PART IV72Item 15.Exhibits, Financial Statement Schedules72Item 16.Form 10-K Summary74 SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain matters discussed in this report may constitute forward-looking statements for purposes of the SecuritiesAct of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the“Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause ouractual results, performance or achievements to be materially different from the future results, performance orachievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,”“e